Clinical Trial: A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07500506) titled 'A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine' on March 23.

Brief Summary: The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine.

This study is seeking participants who:

* are generally healthy and 7 years of age and older,

* have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4.

* are not currently taking, or haven't recently taken, medicines like chem...